GlassScriptPhysician profile
Taleb N Taha
NPI 1407161003
$1,064.57
in general payments reported to CMS, 2019-2025
15 companies · $72.40 in 2025
The $72.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $105 · 2021: $84.61 · 2022: $82.86 · 2023: $266 · 2024: $219 · 2025: $72.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $197.91 | 2019-2024 | Xarelto |
| Pfizer INC. | $186.51 | 2019-2025 | |
| Abbvie INC. | $119.21 | 2021-2025 | Dalvance |
| Novartis Pharmaceuticals Corporation | $102.99 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $68.45 | 2023-2024 | Inpefa |
| Allergan, INC. | $64.83 | 2019-2020 | |
| Gilead Sciences, INC. | $64.22 | 2023-2024 | Veklury |
| Astrazeneca Pharmaceuticals LP | $57.87 | 2019-2024 | Farxiga |
| Mylan Specialty L.P. | $46.22 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.27 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.95 | 2019-2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $29.52 | 2023 | Ultomiris |
| Novo Nordisk INC | $19.58 | 2024 | Wegovy |
| Melinta Therapeutics, LLC | $14.91 | 2019 | |
| Acadia Pharmaceuticals INC | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taleb Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.